What question did this study set out to answer?

This research aims to evaluate the effectiveness of SSTNIV in reversing immune suppression and inhibiting myeloma progression.

May 14, 2026Signal Transduction and Targeted Therapy0 citationsOpen Access

SSTNIV, a syndecan-1-targeting peptide chimera, reverses immune suppression and inhibits myeloma progression

This research aims to evaluate the effectiveness of SSTNIV in reversing immune suppression and inhibiting myeloma progression.
Used a peptide chimera, SSTNIV, targeting syndecan-1.
Evaluated its anti-myeloma activity in advanced and relapsed/refractory myeloma.
Assessed immune restoration effects.
SSTNIV significantly reversed immune suppression.
Showed a marked reduction in myeloma progression.
Indicated potential as a promising therapeutic strategy.

's potent anti-myeloma activity and support its potential as a promising therapeutic strategy for advanced and relapsed/refractory MM.

KI fragen

Bookmark

View Full Paper

KI fragen

Bookmark

View Full Paper